Page last updated: 2024-11-08

amifampridine and Multiple Sclerosis, Relapsing-Remitting

amifampridine has been researched along with Multiple Sclerosis, Relapsing-Remitting in 1 studies

Amifampridine: 4-Aminopyridine derivative that acts as a POTASSIUM CHANNEL blocker to increase release of ACETYLCHOLINE from nerve terminals. It is used in the treatment of CONGENITAL MYASTHENIC SYNDROMES.

Multiple Sclerosis, Relapsing-Remitting: The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Mainero, C1
Inghilleri, M1
Pantano, P1
Conte, A1
Lenzi, D1
Frasca, V1
Bozzao, L1
Pozzilli, C1

Trials

1 trial available for amifampridine and Multiple Sclerosis, Relapsing-Remitting

ArticleYear
Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine.
    Neurology, 2004, Jun-08, Volume: 62, Issue:11

    Topics: 4-Aminopyridine; Adult; Amifampridine; Axons; Cross-Over Studies; Double-Blind Method; Electromyogra

2004
chemdatabank.com